Efficacy assessment of VCZ
death, IFI, toxicity, infection, Cancer
INFECTIOUS DISEASES, ALLERGY, INFECTIOUS PROCESS, INFILTRATES, INFECTION, MYCOSES, INVASIVE FUNGAL INFECTION, INVASIVE FUNGAL INFECTION, CANCER
Patients who received VCZ for suspected invasive fungal infection (IFI) were classified according to the Invasive Fungal Infection Group criteria of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Efficacy assessment was performed by a team of three physicians led by the chief physician. The final clinical response to VCZ was evaluated based on the patients’ clinical symptoms, laboratory data, the Galactomannan experiment, 1,3-β-D-glucan experiment, bacteriological findings, and computed tomography. The response was classified as complete, partial, or treatment failure, with a complete response being defined as the resolution of signs and symptoms of the infectious process, including chest X-ray, and a partial response is defined as at least a 50% improvement in pulmonary infiltrates and signs and symptoms of the infection. Treatment failure was defined as the withdrawal of the treatment due to poor response, toxicity, or death associated with the infection (